Karen Facey | Chair HTAi Rare Disease Interest Group
University of Edinburgh

Karen Facey PhD CStat worked in senior statistical roles in the pharmaceutical industry and medicines regulation, before becoming CEO of the first national health technology asssessment (HTA) agency in Scotland in 2000. For the past 20 years Karen has had a portfolio career working internationally to develop HTA with all stakeholders. Over a decade ago she developed an interest in evidence generation to determine the value of rare disease treatments in HTA and has undertaken research in this field with the University of Edinburgh.  Karen also has special interests in patient involvement and generation of RWE and is senior HTA advisor for the RWE4Decisions learning network and lead editor of the book on Patient Involvement in HTA. She founded the HTAi Rare Disease Interest Group and is its inaugural Chair.